- Home
- NRGV vs JANX Comparison
NRGV vs JANX Comparison
Compare NRGV & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRGV | JANX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 727.0M | 840.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRGV | JANX |
|---|---|---|
| Price | $3.55 | $16.35 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $2.00 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 6.5M | 1.4M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $203,671,000.00 | $10,000,000.00 |
| Revenue This Year | $28.93 | N/A |
| Revenue Next Year | $16.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 340.86 | N/A |
| 52 Week Low | $0.75 | $12.12 |
| 52 Week High | $6.65 | $35.34 |
Technical Indicators
Market Signals| Indicator | NRGV | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 67.91 |
| Support Level | $2.95 | $13.00 |
| Resistance Level | $3.54 | $16.60 |
| Average True Range (ATR) | 0.37 | 0.72 |
| MACD | -0.06 | 0.20 |
| Stochastic Oscillator | 2.18 | 95.89 |
Price Performance
Historical ComparisonAbout NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a diversified portfolio of energy storage solutions to third parties, including proprietary gravity, battery, and green hydrogen-based technologies, supported by technology-agnostic energy management software and integration capabilities. Geographical presence in the United States, Australia, and other countries. The majority of its revenue comes from Australia.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.